FABP4 and metabolic dysfunction-associated steatotic liver disease: Pharmacological inhibition or genetic ablation of FABP4 has been shown to be effective in alleviating insulin resistance, atherosclerosis, and nonalcoholic fatty liver disease (17, 18).